In the News

Share

Connect with us

Stay Informed.

Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

1668 News Items found
Q&A
Sandra Brennan with a patient
Dense Breast Tissue & Cancer Risk: What You Should Know

In this Q&A, MSK radiologist Sandra Brennan discusses what is known about the link between breast density and cancer risk.
MSK Kids patient Rihanna Plaza
Thanks to MSK's Expertise in Pediatric Cancer Genomics, Rihanna Goes to Kindergarten

Prognosis for Rihanna’s cancer with an NTRK gene mutation improved with larotrectinib, a targeted therapy.
MSK physician-scientist Charles Sawyers and SKI computational biologist Dana Pe’er
MSK Researchers Discover How Cancer Cells Change Identity To Escape Therapies

Researchers learn how prostate cancer cells change their type to survive treatment.
Feature
A bowl of ginseng root sitting next to a teapot.
Natural Remedies for Dry Mouth (Xerostomia)

Discover some natural remedies for mouth dryness (xerostomia) and mouth sores, common side effects of cancer treatment.
Finding
Two chimpanzees in a field
Cancer Genes in Humans vs. Chimps: Why Are We More Susceptible?

In an unusual collaboration, scientists from MSK and the American Museum of Natural History looked at how the BRCA2 gene differs between humans and chimps. Mutations in this gene are linked to an increased risk of certain cancers, including breast cancer.
Q&A
physiatrist Jesuel Padro-Guzman
Answers to 8 FAQ About Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Peripheral neuropathy is a common side effect of many types of chemotherapy. Learn about what it is, why it happens, and how to treat CIPN.
In the Lab
Scott Lowe
SKI Scientists Solve 30-Year-Old Mystery About p53 Protein — Dubbed ‘Guardian of the Genome’

Rather than promoting genetic chaos, loss of p53 leads to an orderly progression of genetic changes that no one saw coming.
Dr. Bob Li
First Drug Targeting HER2-Mutant Non-Small Cell Lung Cancer Approved by FDA

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
pancreatic surgeon and K12 alum Vinod Balachandran
MSK Program Prepares Clinicians for Careers in Translational Cancer Research

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.
In the Clinic
Shanu Modi
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)

On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.